Briana Contreras

A high-touch specialty pharmacy program that combines pharmacist support, telehealth and value-based care reduced medical costs and improved outcomes for patients with diabetes, according to presenters at the Asembia Specialty Pharmacy Summit.

PBM reform intensifies in 2026 as transparency laws, FTC pressure and experts including Jeffrey Hogan, Stacie B. Dusetzina, Ph.D., and Chad Worz, Pharm.D., spotlight pricing, rebates and patient costs.

A pharmacist-led specialty pharmacy care model presented at AXS26 shows improved A1C control, fewer hospital visits and lower total costs by expanding support beyond medications to include lifestyle, social needs and care coordination for high-risk patients.

A specialty pharmacy model presented at AXS26 shows how expanding pharmacist roles into care management can improve outcomes and support shared savings in value-based care.

$50M fuels Cleveland Clinic AI efforts, launching a "Digital Front Door" to guide patients to the right care, cut ER crowding and improve access.

Chronic low back pain develops from a mix of clinical, psychological, biological and social factors and highlights the subacute phase as a key period for early coordinated care, according to findings from a recent study.

At the AMCP Annual Meeting this week, experts from Prime Therapeutics said virtual navigation and clinical pathways are helping lower acute care use, guide treatment decisions and improve outcomes for patients with cancer.

A CVS Caremark formulary change in May 2025 led to a short increase in patients switching GLP-1 drugs before prescribing trends leveled off, according to Truveta data presented at AMCP.

As CAR-T therapy expands into earlier stages of treatment and new care settings, payers are weighing access, cost savings and utilization management strategies.

At the AMCP Annual Meeting, experts from Prime Therapeutics said education, policy alignment and collaboration can help improve access to precision testing while managing costs.

In this first part of a video interview series, Abby Kim, Pharm.D., of Prime Therapeutics shows how advances such as precision medicine and CAR T therapy are improving outcomes while requiring managed care leaders to rethink value through a long-term lens of cost, toxicity and patient access.

A multinational study found that metformin use was associated with significantly lower odds of esophageal squamous cell carcinoma, supporting further research into its potential role in cancer prevention and treatment.

A study in Translational Psychiatry found that adding rTMS to standard care may quickly improve flu-related sleep issues by targeting brain activity and immune responses linked to insomnia.

New data from the Health Care Cost Institute shows that higher hospital prices and limited competition, not greater use of care, are the main reasons healthcare spending varies widely across U.S. metro areas.

A new study found a specific brain and spinal cord circuit that appears to cause chronic pain after injury and could one day be targeted to treat pain without affecting the body's normal protective pain responses.

CMS boosts Medicare Advantage 2027 rates by 2.48%; Michael Lutz and Ceci Connolly warn MA plans still face inflation and risk-adjustment inequities.

A review of clinical trials and genetic, immune, and environmental factors revealed that Asian patients with advanced HER2-negative gastric cancer generally experience higher response rates and longer survival with immunotherapy than non-Asian patients.

A March 2026 study found that U.S. cancer patients with hypertension, hyperlipidemia or diabetes face consistently higher healthcare costs, which increased steadily from 2012 to 2018, dropped during the COVID-19 pandemic and remain elevated compared with patients without these conditions.

One year after FDA approval, Journavx (suzetrigine) offers a promising non-opioid option for acute pain, but experts have concerns about long-term safety, opioid-sparing effects and real-world use.

A new report found that despite widespread AI adoption in U.S. health systems, many patients still struggle to access care due to gaps in communication, trust and care navigation.

Get clear, expert-backed answers to the biggest questions surrounding the Great Healthcare Plan, with insights from Emma Wager of KFF and industry experts including Jeffrey Casberg, Lindsay Bealor Greenleaf and Luke Greenwalt. This FAQ breaks down what proposed changes to drug pricing, PBMs, subsidies and insurance coverage could mean for your organization — and what to watch as policies take shape.

Doctors should consider both cultural habits and genetic differences when diagnosing skin conditions in Asian children, according to Joseph Lam, M.D., as some are linked to traditions, others to inherited risks and some remain not fully understood.

CEO of Veradermics, Reid Waldman, M.D., shared that faster hair growth and shifting patient views on prescription treatments could play a key role in improving adherence and outcomes for pattern hair loss.

At the 2026 American Academy of Dermatology meeting, Reid Waldman, M.D., shared data showing that Veradermics’ investigational oral drug VDPHL01 produced faster, more consistent and greater hair growth than existing minoxidil treatments.

A new JAMA study compares the U.S. and South Korea, revealing sharper income-driven gaps in access, spending and outcomes, and why policy fixes matter.

Jefferson health and Ipendence Blue Cross are working together to improve early dementia detection and care coordination in primary care, helping patients receive support sooner and stay healthier at home

This FAQ outlines what managed care leaders need to know about emerging oral GLP-1 therapies, including their clinical uses, growing demand and potential impact on healthcare costs and coverage.

Chronic back pain amplifies sound unpleasantness; fMRI links it to sensory circuits, and pain reprocessing therapy may help normalize responses.

CLDN18.2-high gastroesophageal cancer appears more common and could predict a stronger HER2 therapy benefit but a weaker immunotherapy response.

IBX and Jefferson target earlier dementia diagnosis, support caregivers and use AI data to keep patients safely at home and cut costs in new dementia care program.